Sarepta Therapeutics Inc. (SRPT)
Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.73 per share a year ago.
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The therapy has been developed in collaboration with pharma giant Roche RHHBY.
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (SRPT 0.84%), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive.
Sarepta: Should Investors Run For The Exit?
Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolated incident, influenced by the patient's recent CMV infection, and not indicative of systemic issues. With over 800 patients treated and no similar cases, we expect the stock to recover, presenting a buying opportunity for risk-tolerant investors.
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD).
3 Gene Therapy Stocks to Watch Amid Industry Turmoil
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.
Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has died following treatment with its gene therapy ELEVIDYS. Although acute liver injury is a known potential side effect of ELEVIDYS and similar therapies, this level of severity had not been previously reported, the company said in a statement.
